Opioid agonist-antagonist drugs in acute and chronic pain states.
about
Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgeryNalbuphine for postoperative pain treatment in childrenNalbuphine for postoperative pain treatment in childrenMethylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitorsPharmacological strategies for the management of cancer pain in developing countries.N-Cyano-7α-methoxy-carbonyl-6,14-endo-ethenotetra-hydro-northebaine.Enantiomeric separation of meptazinol and its three intermediate enantiomers by capillary electrophoresis: quantitative analysis of meptazinol in pharmaceutical formulations.Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses.Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.Enantioseparation of meptazinol and its three intermediate enantiomers by capillary electrophoresis using a new cationic β-cyclodextrin derivative in single and dual cyclodextrin systems.The mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaineThe effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors.Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applicationsAnalgesic Effect of Preoperative Pentazocine for Laparoscopic Cholecystectomy.NOP receptor mediates anti-analgesia induced by agonist-antagonist opioidsPatient therapeutic education: placing the patient at the centre of the WHO analgesic ladder.Pharmacological Profiles of Oligomerized μ-Opioid Receptors.Opioid receptor targeting ligands for pain management: a review and update.Electroencephalography and analgesics.Buprenorphine for cancer pain: is it ready for prime time?Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal painChallenges to develop novel anti-inflammatory and analgesic drugs.Pharmacokinetics of dinalbuphine sebacate and nalbuphine in Human after Intramuscular Injection of dinalbuphine sebacate in an Extended-Release Formulation.Antinociceptive and Antioxidant Activities of Phytol In Vivo and In Vitro Models.1-Methyl-3-(3-oxocyclo-hex-1-en-yl)azepan-2-one.Geraniol Induces Antinociceptive Effect in Mice Evaluated in Behavioural and Electrophysiological Models.Methadone in combination with medetomidine as premedication prior to ovariohysterectomy and castration in the cat.Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype.Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.Procedural pain and anxiety in paediatric patients in a Mexican emergency department.Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.Perioperative analgesia with a buprenorphine transdermal patch for hallux valgus surgery: a prospective, randomized, controlled study.Comparative Study of Efficacy of Preoperative Nalbuphine Hydrochloride and Pentazocine Lactate on Hemodynamic Response to Tracheal Intubation and Postoperative Analgesia.Attenuating the Agent: Reducing Opioid “Virulence”
P2860
Q21562378-7AE3AB0F-BCE9-4139-A6CC-F5B65FCC703AQ24194755-1FBE8A45-51E5-45EA-87F1-A267AF349F47Q24204019-A8E6A55F-E003-45AA-ACE2-3A6DE4545123Q33702325-5FF614BB-947D-4ACF-AA2B-96E4B76F9F6EQ34134058-E492F067-AA0E-4DB1-8BFC-CD2F9344C739Q34266181-F9B87FFF-299A-4436-B0C8-4703B360852DQ34871850-B0260CAD-C6CE-411C-923E-C5F5F1869A82Q35006895-9B5B875B-0CB5-406C-83FC-7219A27C583BQ35027648-D1120830-AD6C-43A5-B59E-02973FC938C0Q35174164-6731D196-669E-4BB5-B0E0-D5651496896DQ36709875-7E827E4D-5D7B-4B6D-A93E-B4D71280D2E7Q37267983-880022F4-BB7A-4AE6-A530-A5E307B26D41Q37444456-A70D58A5-1F3F-46D3-9B74-A9D36BEECC57Q37621943-113969B5-94BF-46CC-8C52-FEE52EDE626FQ37627378-0806E061-91EE-4D68-8D4E-329E2564A339Q37635222-522171A7-A4C2-429C-A2EA-C6E6D43B0A3EQ37679197-528F7871-3269-4AEE-A181-36D99567FF0FQ38028661-22239E48-034B-48D6-99E2-152E32296585Q38099666-BE548377-6250-44B1-BEF1-5469DE7F6438Q38243938-AAA6D824-792D-439E-9D00-8775814A5968Q38400356-6FFC18A7-20AB-414B-BAB3-CB7658DC96A8Q38941483-06138D22-AC96-43D3-BD4C-BC3A0AAC05DAQ39152323-FE7AC20C-0D63-4B89-8623-1A814046C8FBQ40596893-30BBBC6E-6F23-4B4B-876F-326B78585B6AQ42082458-3F63EA1C-D033-49E0-A260-DF682B3DF332Q46535716-C93375CD-778D-477D-9C20-5C64E6961ECCQ47788996-850975A0-2688-4FAB-94C4-28B2B9E0EF20Q48463805-95492635-3AA2-4379-A8BF-B05E399D4B02Q49923423-BE8EFB9E-FA81-4002-A784-2D08532E4E54Q50588353-53686D6E-6D29-4189-9A3E-97A57718DC1AQ52578077-3B804B48-1A3C-4064-9C69-ADD74CDADD66Q55096156-EFABCE76-D28C-4167-90E2-D8435322D6E1Q55278780-0B3919DF-BE1E-490A-A432-4F6C168D3912Q57462886-309452DB-DEFD-41CC-91BE-03872016580D
P2860
Opioid agonist-antagonist drugs in acute and chronic pain states.
description
1991 nî lūn-bûn
@nan
1991 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի մարտին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Opioid agonist-antagonist drugs in acute and chronic pain states.
@ast
Opioid agonist-antagonist drugs in acute and chronic pain states.
@en
Opioid agonist-antagonist drugs in acute and chronic pain states.
@nl
type
label
Opioid agonist-antagonist drugs in acute and chronic pain states.
@ast
Opioid agonist-antagonist drugs in acute and chronic pain states.
@en
Opioid agonist-antagonist drugs in acute and chronic pain states.
@nl
prefLabel
Opioid agonist-antagonist drugs in acute and chronic pain states.
@ast
Opioid agonist-antagonist drugs in acute and chronic pain states.
@en
Opioid agonist-antagonist drugs in acute and chronic pain states.
@nl
P1433
P1476
Opioid agonist-antagonist drugs in acute and chronic pain states.
@en
P2093
P304
P356
10.2165/00003495-199141030-00002
P577
1991-03-01T00:00:00Z
P6179
1020150440